Leerink Partners Downgrades Reneo Pharmaceuticals to Market Perform, Announces $1 Price Target
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Joseph Schwartz has downgraded Reneo Pharmaceuticals (NASDAQ:RPHM) from Outperform to Market Perform and set a price target of $1.
December 15, 2023 | 9:54 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Reneo Pharmaceuticals was downgraded by Leerink Partners from Outperform to Market Perform with a new price target of $1.
Downgrades by analysts can lead to a negative perception among investors and a potential decrease in stock price. The new price target of $1 suggests a bearish outlook on the stock's future performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100